Abstract
In this issue, Eichhorst and colleagues show in a large randomized phase 3 clinical trial that combination therapy using fludarabine and cyclophosphamide is superior to fludarabine alone for younger previously untreated CLL patients. In addition, they found a reduced level of clinical responses when imaging was considered as part of restaging compared with responses defined by recommended NCI standards.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 848 |
| Number of pages | 1 |
| Journal | Blood |
| Volume | 107 |
| Issue number | 3 |
| DOIs | |
| State | Published - Feb 1 2006 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology